# Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

> **NCT01776541** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 979 (actual)

## Conditions studied

- Pandemic H5N1 Influenza

## Interventions

- **BIOLOGICAL:** Adjuvanted H5N1 pandemic influenza vaccine

## Key facts

- **NCT ID:** NCT01776541
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-06
- **Final completion:** 2014-05
- **Target enrollment:** 979 (ACTUAL)
- **Last updated:** 2015-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776541, "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01776541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*